pillbase.ru

Rystiggo

Active substance: rozanolixizumab

rozanolixizumab

Centralised EU authorisationActive

Marketing holder: UCB Pharma

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • RYSTIGGO
    INJECTION, SOLUTION · ROZANOLIXIZUMAB 140 mg/mL
    50474-980
    UCB, Inc.
  • RYSTIGGO
    INJECTION, SOLUTION · ROZANOLIXIZUMAB 140 mg/mL
    50474-981
    UCB, Inc.
  • RYSTIGGO
    INJECTION, SOLUTION · ROZANOLIXIZUMAB 140 mg/mL
    50474-983
    UCB, Inc.
  • RYSTIGGO
    INJECTION, SOLUTION · ROZANOLIXIZUMAB 140 mg/mL
    50474-982
    UCB, Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208e-6171-7174-b5be-08008f72ff21,01a1208f-cdce-7ea7-b16d-7b155bdd21f4,01a12093-979f-713e-b37d-70616c1717ef,01a12098-bdb4-70a2-b3fa-5daf793d2661;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/005824
Registration status
Active
ATC code
L04AL02
Sources
  • product · EMA · EMEA/H/C/005824 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/005824 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/005824 · Verified 2026-10-09